{"preliminary_commentary":{"by_channel":{"x_thread":25,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06841055\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT06841055","nct_id":"NCT06841055","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06841055. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Part 1A - Pumitamig Dose 1 + docetaxel","type":"EXPERIMENTAL"},{"description":null,"label":"Part 1B - Pumitamig Dose 2 + docetaxel","type":"EXPERIMENTAL"},{"description":"Pumitamig and docetaxel will be administered at the dose level recommended by an internal review committee based on the observed safety profile from Part 1.","label":"Part 2: Selected doses of pumitamig + docetaxel","type":"EXPERIMENTAL"}],"collaborators":["BioNTech (Shanghai) Pharmaceuticals Co., Ltd."],"completion_date":{"date":"2028-10","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":60,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pumitamig","otherNames":["BNT327","PM8002","BMS-986545"],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-24","lead_sponsor":"BioNTech SE","official_title":"A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1 - Occurrence of dose limiting toxicities (DLTs)","timeFrame":"Up to 21 days after first dose of investigational medicinal product (IMP)"},{"measure":"Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest","timeFrame":"From initiation of the first dose of IMP to the 90-day Follow-Up visit"},{"measure":"Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events","timeFrame":"From initiation of the first dose of IMP until the 90-day Safety Follow-up visit"},{"measure":"Part 1 and Part 2 - Objective response rate","timeFrame":"Up to approximately 2 years"}],"references":[],"start_date":{"date":"2025-03-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment","url":"https://clinicaltrials.gov/study/NCT06841055"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06841055"}